Menstrual Blood Sequencing Effective for HPV Screening
Screening for human papillomavirus (HPV) in high-risk individuals may be done effectively and noninvasively using menstrual blood testing with target-capture sequencing, a clinical study suggests. The researchers collected 137 sanitary pads with menstrual blood from 120 women who had already had high-risk HPV detected using a traditional method, cervical HPV GenoArray testing. Researchers completed target capture sequencing of menstrual blood samples to identify high-risk HPV genotypes and see if these findings were concordant with cervical HPV GenoArray results. Overall, the concordance rate between menstrual blood sample sequencing and cervical HPV GenoArray testing was 92.7%, the authors report in JAMA Network Open.
@dimple There were 24 menstrual blood samples that had incomplete concordance or discordant results when compared with cervical tissue samples. This included 11 samples that had additional high-risk HPV genotypes, 5 true-negative samples, and 2 samples with high-risk HPV genotypes correctly identified by target-capture screening. When researchers looked at outcomes based on different menstrual cycle days used for blood sample collection, the found detection of high-risk HPV was similar on different cycle days. The menstrual blood high-risk HPV positivity rate was 96.4% on menstrual cycle day 1, 91.2% on menstrual cycle day 2, and 96.4% on menstrual cycle day 3. All four samples from menstrual cycle day four were positive as well. In addition, the sensitivity of high-risk HPV screening based on sequencing of menstrual blood samples was 97.7%